Vanguard Group Inc. trimmed its stake in shares of Novanta Inc. (NASDAQ:NOVT – Free Report) by 0.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,340,698 shares of the technology company’s stock after selling 38,190 shares during the quarter. Vanguard Group Inc. owned about 12.13% of Novanta worth $516,500,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds also recently added to or reduced their stakes in the company. Pilgrim Partners Asia Pte Ltd purchased a new position in shares of Novanta during the 3rd quarter worth approximately $36,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Novanta during the 3rd quarter worth approximately $40,000. Danske Bank A S purchased a new position in shares of Novanta during the 3rd quarter worth approximately $40,000. Farther Finance Advisors LLC raised its stake in shares of Novanta by 1,291.4% during the 4th quarter. Farther Finance Advisors LLC now owns 487 shares of the technology company’s stock worth $58,000 after buying an additional 452 shares in the last quarter. Finally, Assetmark Inc. raised its stake in shares of Novanta by 22.4% during the 4th quarter. Assetmark Inc. now owns 541 shares of the technology company’s stock worth $64,000 after buying an additional 99 shares in the last quarter. 98.35% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling at Novanta
In other news, CFO Robert Buckley sold 9,957 shares of the firm’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $116.77, for a total transaction of $1,162,678.89. Following the sale, the chief financial officer owned 96,616 shares in the company, valued at $11,281,850.32. This trade represents a 9.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Matthijs Glastra sold 6,500 shares of the firm’s stock in a transaction on Friday, April 17th. The stock was sold at an average price of $130.05, for a total value of $845,325.00. Following the sale, the chief executive officer owned 56,761 shares in the company, valued at $7,381,768.05. This trade represents a 10.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 25,380 shares of company stock worth $3,296,276 in the last 90 days. Insiders own 1.20% of the company’s stock.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Analysis on Novanta
Novanta Stock Performance
Novanta stock opened at $126.08 on Tuesday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.80 and a current ratio of 3.69. The stock has a fifty day moving average of $126.19 and a two-hundred day moving average of $124.42. The company has a market capitalization of $4.49 billion, a price-to-earnings ratio of 86.36 and a beta of 1.62. Novanta Inc. has a fifty-two week low of $98.27 and a fifty-two week high of $149.95.
Novanta (NASDAQ:NOVT – Get Free Report) last released its quarterly earnings results on Monday, February 23rd. The technology company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.03. The company had revenue of $258.35 million during the quarter, compared to the consensus estimate of $260.72 million. Novanta had a return on equity of 13.12% and a net margin of 5.49%.During the same quarter last year, the business posted $0.76 earnings per share. Novanta has set its FY 2026 guidance at 3.500-3.650 EPS and its Q1 2026 guidance at 0.750-0.800 EPS. On average, analysts anticipate that Novanta Inc. will post 3.54 EPS for the current fiscal year.
Novanta Profile
Novanta, Inc (NASDAQ: NOVT) is a global technology company that designs and manufactures precision components, subsystems and software used in advanced photonics and motion control applications. The company serves customers in the medical device and advanced industrial markets, supplying critical technologies for diagnostics and therapeutic systems, semiconductor and electronics manufacturing, and scientific instrumentation. Novanta’s product portfolio includes laser control modules, optics, beam delivery systems, high-precision motors, actuators, stages, and fluidics solutions designed to meet stringent accuracy and reliability requirements.
Novanta’s Photonics segment delivers laser and energy delivery components that enable minimally invasive surgical procedures and diagnostic imaging.
See Also
Want to see what other hedge funds are holding NOVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novanta Inc. (NASDAQ:NOVT – Free Report).
Receive News & Ratings for Novanta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novanta and related companies with MarketBeat.com's FREE daily email newsletter.
